Cancer Immunotherapy Market (2024 - 2034)
Cancer Immunotherapy Market Study by Monoclonal Antibodies, Immune Checkpoint Inhibitors, Immune System Modulators, and Cancer Immunotherapy Vaccines from 2024 to 2034
Core Findings
FREE CustomizationCancer Immunotherapy Market (2024 to 2034)
The global cancer immunotherapy market is set to garner US$ 159.2 billion in revenue in 2024, according to Fact.MR, a market research and intelligence provider. Worldwide demand for cancer immunotherapies is projected to increase at a CAGR of 10% and reach a market value of US$ 412.8 billion by 2034.
Rising popularity of immunotherapy treatment due to its effective results is set to boost the overall market growth during the forecast period. The majority of leading companies are focused on the production of advanced drug solutions to support the effectiveness of immunotherapies. Furthermore, these industry giants are investing heavily in research and development activities.
The COVID-19 pandemic opened up new growth prospects for key manufacturers to focus on the production of anti-cancer drugs and cancer therapeutics. Need to prevent complications among cancer patients infected by the coronavirus also exacerbated the need for advanced critical care. The current scenario showcases that the growing prevalence of cancer and the importance of disbursing effective therapeutic approaches for cancer are driving the focus of governments on increased healthcare spending worldwide.
In most cancer cases, surgical procedures are opted to remove the tumor. Growing need for novel delivery approaches to cancer treatment is leading to the integration of peptide-based therapies and peptide-based drugs for effective results. These are some of the emerging cancer immunotherapy market trends to be followed over the coming years.
- The North American cancer immunotherapy market size is calculated to reach US$ 100.3 billion by 2034.
- East Asia is expected to capture 22.4% of the global cancer immunotherapy market share in 2024.
| Report Attribute | Detail |
|---|---|
| Cancer Immunotherapy Market Size (2024E) | US$ 159.2 Billion |
| Forecasted Market Value (2034F) | US$ 412.8 Billion |
| Global Market Growth Rate (2024 to 2034) | 10% CAGR |
| South Korea Market Value (2034F) | US$ 22 Billion |
| Cancer Immunotherapy Vaccine Demand Growth (2024 to 2034) | 10.1% CAGR |
| Key Companies Profiled | Eli Lilly and Company; Pfizer, Inc.; Spectrum Pharmaceuticals, Inc.; GlaxoSmithKline Plc.; Amgen Inc.; Bristol-Myers Squibb Company; Janssen Biotech, Inc.; Novartis AG; AstraZeneca Plc.; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; Sanofi; Takeda Pharmaceuticals; Immunocore, Ltd. |
Which Dynamics are Influencing the Popularity of Cancer Immunotherapies?
“Novel Cancer Biomarkers Offering Effective Analysis for Immunotherapies”
Some of the leading companies are focusing on the use of novel biomarkers for effective cancer diagnosis and treatment. Biomarkers are effective cancer diagnostic indicators that provide full cancer analysis from the type of cancer to what kind of molecular dysregulation caused the progression of the disease. Development of biomarkers for immunotherapy at the cellular, soluble, and genomic levels is set to boost the profits of key producers over the coming years. Some of the biomarkers in immunotherapy include serum proteins, receptor expression patterns, and tumor microenvironment biomarkers.
“Increasing Cancer Burden Spurring Demand for Advanced Cancer Immunotherapies”
- According to the National Center for Biotechnology Information, in 2023, 1,958,310 new cancer cases and 609,820 cancer deaths were projected to occur in the United States.
- As per analysis by the World Health Organization (WHO), breast cancer is one of the most common malignancies in women worldwide.
- According to the same source, in 2022, the number of females living with breast cancer was around 2.3 million, and 670,000 deaths were noted due to breast cancer across the globe.
Global cases of cancer are expected to increase at a swift pace over the next 10 years. As such, governments across the world are investing heavily in the development of sustainable infrastructure for disseminating cancer by providing effective diagnostics and treatment measures. These aspects are set to offer high-growth opportunities for cancer immunotherapy providers.
Why is Cancer Immunotherapy a High-Growth Yet Challenging Field?
“Capital-Intensive Nature and Low Success Chances of Immunotherapy”
Several studies show that cancer is an extremely complex disease, and there is no single cure that can prove to be effective for all patients. However, key players in the cancer immunotherapy market are leveraging this opportunity to reach the optimum efficacy level of therapeutics to treat cancer with minimal side effects.
Key requisite to achieve product innovation is high working capital for experimentation and clinical trials, which poses challenges for manufacturers. Besides this, the risk of drug rejection leads to the wastage of resources. Studies also estimate that only 5% of anticancer drugs gain commercial license, post the success of Phase III trials, which is indicative of the high rejection rate of therapeutics in the cancer immunotherapy industry.
Start-up Ecosystem
- Nouscom is a Swiss start-up that manufactures viral-vectored genetic vaccines. The company offers NOUS-209, its leading immunotherapy candidate effective in the treatment of microsatellite instability (MSI) tumors and mismatch repair deficiency (dMMR).
- Palleon Pharmaceuticals is a start-up based in the United States that is focused on the development of immunosuppressive sialoglycan-sensing receptors in cells to treat cancer tumors. The company offers two technology platforms EAGLE (Enzyme-Antibody Glyco-Ligand Editing) and Convergence.
Country-wise Analysis
Why Do Cancer Immunotherapy Producers Have Huge Research and Manufacturing Units in the United States?
“Supportive Government Policies Boosting Growth of Cancer Drug Suppliers”
| Attribute | United States |
|---|---|
| Market Value (2024E) | US$ 16.9 Billion |
| Growth Rate (2024 to 2034) | 10.5% CAGR |
| Projected Value (2034F) | US$ 45.7 Billion |
The United States leads the North American market and is set to capture a share of 45.6% by 2034. This can be attributed to favorable market dynamics such as progressive improvements in healthcare infrastructure and government initiatives in the mode of subsidies supporting key market players in carrying out R&D activities. Furthermore, market players are also expected to receive benefits from the United States federal government, such as tax exemptions and market exclusivity. Growing number of awareness campaigns regarding the diagnosis and treatment of cancer is also complementing cancer immunotherapy demand growth in the United States.
Will Rising Cancer Prevalence Push Immunotherapy Demand in Japan?
“Rapidly Increasing Geriatric Population with Chronic Disorders and Altering Lifestyles of Adults”
| Attribute | Japan |
|---|---|
| Market Value (2024E) | US$ 10.3 Billion |
| Growth Rate (2024 to 2034) | 10.5% CAGR |
| Projected Value (2034F) | US$ 28 Billion |
- According to a BMC Medicine report, Asia accounts for half of the global cancer burden, with cancer incidence projected to rise to nearly 10.6 million by 2030.
- Japan is estimated to account for 28.9% of the East Asia market share in 2024.
Rapidly aging population, busy and stressful lifestyles, and socio-economic changes are expected to be lead to increasing cases of cancer in Japan. Most common cancer types include those of the lungs, breast, and colon. Furthermore, increased healthcare spending on developing advanced research & development facilities for designing high-grade oncology diagnostics and treatment solutions is set to boost the cancer immunotherapy market growth by 2034.
Category-wise Analysis
Which Cancer Type is Driving High Demand for Effective Immunotherapy?
“Lung Cancer Most Common Type of Malignancy”
- According to the American Cancer Society, around one-quarter of deaths are due to lung cancer in the United States. Apart from prostate cancer in men and breast cancer in women, lung cancer is the most common cancer diagnosed in people. This is believed to be due to increased smoking habits and intake of harmful drugs.
In addition, chances of lung cancer being detected at an early stage are less. Thus, rising cases of lung cancer worldwide are driving target patients’ attention toward cancer immunotherapies for better treatment.
What’s Boosting Demand for Immune Checkpoint Inhibitors?
“Ability of Immune Checkpoint Inhibitors to Trigger Antitumor Immune Response”
| Attribute | Immune Checkpoint Inhibitors |
|---|---|
| Segment Value (2024E) | US$ 38.5 Billion |
| Growth Rate (2024 to 2034) | 10.1% CAGR |
| Projected Value (2034F) | US$ 100.7 Billion |
Immune checkpoints are a part of the immune system that majorly focus on the protection of healthy cells in the body during the treatment process. Immune checkpoint inhibitors stop the 'off' signal transmission and allow T cells to kill cancer. Immune checkpoint inhibitors are majorly used for the treatment of cancer.
Monoclonal antibody-based drugs also assist in flagging cancer cells, triggering cell-membrane destruction, inhibiting malignant cell proliferation, preventing blood vessel growth, easy chemotherapy delivery, and binding cancer and immune cells among other benefits.
Why Do Cancer Research Centers Account for a Leading Market Share?
“Cancer Research Centers Offer Advanced and Effective Immunotherapies”
| Attribute | Cancer Research Centers |
|---|---|
| Segment Value (2024E) | US$ 43.9 Billion |
| Growth Rate (2024 to 2034) | 10% CAGR |
| Projected Value (2034F) | US$ 113.9 Billion |
Even though hospitals are the most favored medical settings, cancer research centers are equipped with advanced technologies that help offer effective diagnosis and treatment. Cancer research centers are institutions where studies related to cancer, research, and development of advanced diagnostic and treatment procedures are carried out. These centers also offer treatment to cancer patients.
Presence of advanced diagnostics and treatment equipment, medical professionals, and scientists, as well as therapeutics, supported by public and private funding, further improves the healthcare quality offered by research centers.
Competitive Landscape
Leading companies are capitalizing on conducting extensive clinical trials to verify the efficacy of various immunotherapy approaches, including vaccinations and oral drugs. Furthermore, market players are funding research studies to ascertain patterns of cancer prevalence across key geographies.
- In March 2024, the United States Food and Drug Administration (FDA) approved Bristol Myers Squibb’s ‘Opdivo® (nivolumab)’ in combination with gemcitabine and cisplatin for the first-line treatment of unresectable or metastatic urothelial carcinoma (UC) of adult patients.
- In 2021, Amgen Plc. announced its first combination study results from its Phase 1b/2 CodeBreaK 101 study, a comprehensive global clinical development program in patients with KRAS G12C-mutated advanced colorectal cancer. It showed that combining LUMAKRASTM (sotorasib) with Vectibix® (panitumumab) demonstrates efficacy and safety.
- In September 2021, Bristol-Myers Squibb Company conducted a survey that included 250 oncologists, surgeons, and specialists from countries such as the United States, Germany, and Japan. The survey revealed that immunotherapy has the potential to kill early-stage cancer.
Fact.MR provides detailed information about the price points of key providers of cancer immunotherapies positioned across the world, sales growth, production capacity, and speculative technological expansion, in the recently updated market report.
Key Segments of Cancer Immunotherapy Market Research
-
By Therapy :
- Monoclonal Antibodies
- Immune Checkpoint Inhibitors
- Immune System Modulators
- Cancer Immunotherapy Vaccines
- Others
-
By Cancer Type :
- Lung
- Colorectal
- Breast
- Prostate
- Melanoma
- Blood
- Others
-
By End User :
- Hospitals
- Ambulatory Surgical Centers
- Cancer Research Centers
- Clinics
-
By Region :
- North America
- Latin America
- Western Europe
- Eastern Europe
- East Asia
- South Asia & Pacific
- Middle East & Africa
Table of Content
- 1. Executive Summary
- 2. Industry Introduction, including Taxonomy and Market Definition
- 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments
- 4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections
- 5. Pricing Analysis
- 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034
- 6.1. Therapy
- 6.2. Cancer Type
- 6.3. End User
- 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Therapy
- 7.1. Monoclonal Antibodies
- 7.2. Immune Checkpoint Inhibitors
- 7.3. Immune System Modulators
- 7.4. Vaccines
- 7.5. Others
- 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Cancer Type
- 8.1. Lung
- 8.2. Colorectal
- 8.3. Breast
- 8.4. Prostate
- 8.5. Melanoma
- 8.6. Blood
- 8.7. Others
- 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by End User
- 9.1. Hospitals
- 9.2. Ambulatory Surgical Centers
- 9.3. Cancer Research Centers
- 9.4. Clinics
- 10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Region
- 10.1. North America
- 10.2. Latin America
- 10.3. Western Europe
- 10.4. Eastern Europe
- 10.5. East Asia
- 10.6. South Asia & Pacific
- 10.7. Middle East & Africa
- 11. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 12. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 13. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 14. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 15. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 16. South Asia & Pacific Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 17. Middle East & Africa Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 18. Sales Forecast 2024 to 2034 by Therapy, Cancer Type, End User, and Region for 30 Countries
- 19. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard
- 20. Company Profile
- 20.1. Eli Lilly and Company
- 20.2. Pfizer, Inc.
- 20.3. Spectrum Pharmaceuticals, Inc.
- 20.4. GlaxoSmithKline Plc.
- 20.5. Amgen Inc.
- 20.6. Bristol-Myers Squibb Company
- 20.7. Janssen Biotech, Inc.
- 20.8. Novartis AG
- 20.9. AstraZeneca Plc.
- 20.10. F. Hoffmann-La Roche Ltd.
- 20.11. Merck & Co., Inc.
- 20.12. Sanofi
- 20.13. Takeda Pharmaceuticals
- 20.14. Immunocore, Ltd
- 21. Assumptions and Acronyms Therapy
- 22. Research Methodology
List Of Table
Table 01: Global Market Value (US$ Mn) Analysis, by Therapy, 2019 to 2023
Table 02: Global Market Value (US$ Mn) Analysis, by Therapy, 2024 to 2034
Table 03: Global Market Value (US$ Mn) Opportunity Analysis, by Therapy, 2024 to 2034
Table 04: Global Market Value (US$ Mn) Analysis, by Cancer Type, 2019 to 2023
Table 05: Global Market Value (US$ Mn) Analysis, by Cancer Type, 2024 to 2034
Table 06: Global Market Value (US$ Mn) Opportunity Analysis, by Cancer Type, 2024 to 2034
Table 07: Global Market Value (US$ Mn) Analysis, by End User, 2019 to 2023
Table 08: Global Market Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 09: Global Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
Table 10: Global Market Value (US$ Mn) Analysis, by Region, 2019 to 2023
Table 11: Global Market Value (US$ Mn) Analysis, by Region, 2024 to 2034
Table 12: Global Market Value (US$ Mn) Opportunity Analysis, by Region, 2024 to 2034
Table 13: North America Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 14: North America Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 15: North America Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 16: North America Market Value (US$ Mn) Analysis, by Therapy, 2019 to 2023
Table 17: North America Market Value (US$ Mn) Analysis, by Therapy, 2024 to 2034
Table 18: North America Market Value (US$ Mn) Opportunity Analysis, by Therapy, 2024 to 2034
Table 19: North America Market Value (US$ Mn) Analysis, by Cancer Type, 2019 to 2023
Table 20: North America Market Value (US$ Mn) Analysis, by Cancer Type, 2024 to 2034
Table 21: North America Market Value (US$ Mn) Opportunity Analysis, by Cancer Type, 2024 to 2034
Table 22: North America Market Value (US$ Mn) Analysis, by End User, 2019 to 2023
Table 23: North America Market Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 24: North America Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
Table 25: Latin America Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 26: Latin America Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 27: Latin America Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 28: Latin America Market Value (US$ Mn) Analysis, by Therapy, 2019 to 2023
Table 29: Latin America Market Value (US$ Mn) Analysis, by Therapy, 2024 to 2034
Table 30: Latin America Market Value (US$ Mn) Opportunity Analysis, by Therapy, 2024 to 2034
Table 31: Latin America Market Value (US$ Mn) Analysis, by Cancer Type, 2019 to 2023
Table 32: Latin America Market Value (US$ Mn) Analysis, by Cancer Type, 2024 to 2034
Table 33: Latin America Market Value (US$ Mn) Opportunity Analysis, by Cancer Type, 2024 to 2034
Table 34: Latin America Market Value (US$ Mn) Analysis, by End User, 2019 to 2023
Table 35: Latin America Market Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 36: Latin America Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
Table 37: Western Europe Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 38: Western Europe Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 39: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 40: Western Europe Market Value (US$ Mn) Analysis, by Therapy, 2019 to 2023
Table 41: Western Europe Market Value (US$ Mn) Analysis, by Therapy, 2024 to 2034
Table 42: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Therapy, 2024 to 2034
Table 43: Western Europe Market Value (US$ Mn) Analysis, by Cancer Type, 2019 to 2023
Table 44: Western Europe Market Value (US$ Mn) Analysis, by Cancer Type, 2024 to 2034
Table 45: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Cancer Type, 2024 to 2034
Table 46: Western Europe Market Value (US$ Mn) Analysis, by End User, 2019 to 2023
Table 47: Western Europe Market Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 48: Western Europe Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
Table 49: Eastern Europe Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 50: Eastern Europe Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 51: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 52: Eastern Europe Market Value (US$ Mn) Analysis, by Therapy, 2019 to 2023
Table 53: Eastern Europe Market Value (US$ Mn) Analysis, by Therapy, 2024 to 2034
Table 54: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Therapy, 2024 to 2034
Table 55: Eastern Europe Market Value (US$ Mn) Analysis, by Cancer Type, 2019 to 2023
Table 56: Eastern Europe Market Value (US$ Mn) Analysis, by Cancer Type, 2024 to 2034
Table 57: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Cancer Type, 2024 to 2034
Table 58: Eastern Europe Market Value (US$ Mn) Analysis, by End User, 2019 to 2023
Table 59: Eastern Europe Market Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 60: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
Table 61: East Asia Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 62: East Asia Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 63: East Asia Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 64: East Asia Market Value (US$ Mn) Analysis, by Therapy, 2019 to 2023
Table 65: East Asia Market Value (US$ Mn) Analysis, by Therapy, 2024 to 2034
Table 66: East Asia Market Value (US$ Mn) Opportunity Analysis, by Therapy, 2024 to 2034
Table 67: East Asia Market Value (US$ Mn) Analysis, by Cancer Type, 2019 to 2023
Table 68: East Asia Market Value (US$ Mn) Analysis, by Cancer Type, 2024 to 2034
Table 69: East Asia Market Value (US$ Mn) Opportunity Analysis, by Cancer Type, 2024 to 2034
Table 70: East Asia Market Value (US$ Mn) Analysis, by End User, 2019 to 2023
Table 71: East Asia Market Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 72: East Asia Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
Table 73: South Asia & Pacific Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 74: South Asia & Pacific Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 75: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 76: South Asia & Pacific Market Value (US$ Mn) Analysis, by Therapy, 2019 to 2023
Table 77: South Asia & Pacific Market Value (US$ Mn) Analysis, by Therapy, 2024 to 2034
Table 78: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Therapy, 2024 to 2034
Table 79: South Asia & Pacific Market Value (US$ Mn) Analysis, by Cancer Type, 2019 to 2023
Table 80: South Asia & Pacific Market Value (US$ Mn) Analysis, by Cancer Type, 2024 to 2034
Table 81: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Cancer Type, 2024 to 2034
Table 82: South Asia & Pacific Market Value (US$ Mn) Analysis, by End User, 2019 to 2023
Table 83: South Asia & Pacific Market Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 84: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
Table 85: MEA Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 86: MEA Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 87: MEA Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 88: MEA Market Value (US$ Mn) Analysis, by Therapy, 2019 to 2023
Table 89: MEA Market Value (US$ Mn) Analysis, by Therapy, 2024 to 2034
Table 90: MEA Market Value (US$ Mn) Opportunity Analysis, by Therapy, 2024 to 2034
Table 91: MEA Market Value (US$ Mn) Analysis, by Cancer Type, 2019 to 2023
Table 92: MEA Market Value (US$ Mn) Analysis, by Cancer Type, 2024 to 2034
Table 93: MEA Market Value (US$ Mn) Opportunity Analysis, by Cancer Type, 2024 to 2034
Table 94: MEA Market Value (US$ Mn) Analysis, by End User, 2019 to 2023
Table 95: MEA Market Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 96: MEA Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
List Of Figures
Figure 01: Global Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 02: Global Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 03: Global Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 04: Global Market Incremental $ Opportunity, 2024 to 2034
Figure 05: Global Market Share and BPS Analysis by Therapy, 2024 & 2034
Figure 06: Global Market Y-o-Y Growth Projections by Therapy, 2024 to 2034
Figure 07: Global Market Attractiveness Analysis by Therapy, 2024 to 2034
Figure 08: Global Market Share and BPS Analysis by Cancer Type, 2024 & 2034
Figure 09: Global Market Y-o-Y Growth Projections by Cancer Type, 2024 to 2034
Figure 10: Global Market Attractiveness Analysis by Cancer Type, 2024 to 2034
Figure 11: Global Market Share and BPS Analysis by End User, 2024 & 2034
Figure 12: Global Market Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 13: Global Market Attractiveness Analysis by End User, 2024 to 2034
Figure 14: Global Market Share and BPS Analysis by Region, 2024 & 2034
Figure 15: Global Market Y-o-Y Growth Projections by Region, 2024 to 2034
Figure 16: Global Market Attractiveness Analysis by Region, 2024 to 2034
Figure 17: North America Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 18: North America Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 19: North America Market Value Y-o-Y Growth and Forecast, 2034
Figure 20: North America Market Incremental $ Opportunity, 2024 to 2034
Figure 21: North America Market Share Analysis by Country, 2024 & 2034
Figure 22: North America Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 23: North America Market Attractiveness Analysis by Country, 2024 to 2034
Figure 24: North America Market Share and BPS Analysis by Therapy, 2024 & 2034
Figure 25: North America Market Y-o-Y Growth Projections by Therapy, 2024 to 2034
Figure 26: North America Market Attractiveness Analysis by Therapy, 2024 to 2034
Figure 27: North America Market Share and BPS Analysis by Cancer Type, 2024 & 2034
Figure 28: North America Market Y-o-Y Growth Projections by Cancer Type, 2024 to 2034
Figure 29: North America Market Attractiveness Analysis by Cancer Type, 2024 to 2034
Figure 30: North America Market Share and BPS Analysis by End User, 2024 & 2034
Figure 31: North America Market Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 32: North America Market Attractiveness Analysis by End User, 2024 to 2034
Figure 33: Latin America Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 34: Latin America Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 35: Latin America Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 36: Latin America Market Incremental $ Opportunity, 2024 to 2034
Figure 37: Latin America Market Share Analysis by Country, 2024 & 2034
Figure 38: Latin America Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 39: Latin America Market Attractiveness Analysis by Country, 2024 to 2034
Figure 40: Latin America Market Share and BPS Analysis by Therapy, 2024 & 2034
Figure 41: Latin America Market Y-o-Y Growth Projections by Therapy, 2024 to 2034
Figure 42: Latin America Market Attractiveness Analysis by Therapy, 2024 to 2034
Figure 43: Latin America Market Share and BPS Analysis by Cancer Type, 2024 & 2034
Figure 44: Latin America Market Y-o-Y Growth Projections by Cancer Type, 2024 to 2034
Figure 45: Latin America Market Attractiveness Analysis by Cancer Type, 2024 to 2034
Figure 46: Latin America Market Share and BPS Analysis by End User, 2024 & 2034
Figure 47: Latin America Market Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 48: Latin America Market Attractiveness Analysis by End User, 2024 to 2034
Figure 49: Western Europe Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 50: Western Europe Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 51: Western Europe Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 52: Western Europe Market Incremental $ Opportunity, 2024 to 2034
Figure 53: Western Europe Market Share Analysis by Country, 2024 & 2034
Figure 54: Western Europe Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 55: Western Europe Market Attractiveness Analysis by Country, 2024 to 2034
Figure 56: Western Europe Market Share and BPS Analysis by Therapy, 2024 & 2034
Figure 57: Western Europe Market Y-o-Y Growth Projections by Therapy, 2024 to 2034
Figure 58: Western Europe Market Attractiveness Analysis by Therapy, 2024 to 2034
Figure 59: Western Europe Market Share and BPS Analysis by Cancer Type, 2024 & 2034
Figure 60: Western Europe Market Y-o-Y Growth Projections by Cancer Type, 2024 to 2034
Figure 61: Western Europe Market Attractiveness Analysis by Cancer Type, 2024 to 2034
Figure 62: Western Europe Market Share and BPS Analysis by End User, 2024 & 2034
Figure 63: Western Europe Market Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 64: Western Europe Market Attractiveness Analysis by End User, 2024 to 2034
Figure 66: Eastern Europe Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 67: Eastern Europe Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 68: Eastern Europe Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 69: Eastern Europe Market Incremental $ Opportunity, 2024 to 2034
Figure 70: Eastern Europe Market Share Analysis by Country, 2024 & 2034
Figure 71: Eastern Europe Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 72: Eastern Europe Market Attractiveness Analysis by Country, 2024 to 2034
Figure 73: Eastern Europe Market Share and BPS Analysis by Therapy, 2024 & 2034
Figure 74: Eastern Europe Market Y-o-Y Growth Projections by Therapy, 2024 to 2034
Figure 75: Eastern Europe Market Attractiveness Analysis by Therapy, 2024 to 2034
Figure 76: Eastern Europe Market Share and BPS Analysis by Cancer Type, 2024 & 2034
Figure 77: Eastern Europe Market Y-o-Y Growth Projections by Cancer Type, 2024 to 2034
Figure 78: Eastern Europe Market Attractiveness Analysis by Cancer Type, 2024 to 2034
Figure 79: Eastern Europe Market Share and BPS Analysis by End User, 2024 & 2034
Figure 80: Eastern Europe Market Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 81: Eastern Europe Market Attractiveness Analysis by End User, 2024 to 2034
Figure 82: East Asia Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 83: East Asia Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 84: East Asia Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 85: East Asia Market Incremental $ Opportunity, 2024 to 2034
Figure 86: East Asia Market Share Analysis by Country, 2024 & 2034
Figure 87: East Asia Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 88: East Asia Market Attractiveness Analysis by Country, 2024 to 2034
Figure 89: East Asia Market Share and BPS Analysis by Therapy, 2024 & 2034
Figure 90: East Asia Market Y-o-Y Growth Projections by Therapy, 2024 to 2034
Figure 91: East Asia Market Attractiveness Analysis by Therapy, 2024 to 2034
Figure 92: East Asia Market Share and BPS Analysis by Cancer Type, 2024 & 2034
Figure 93: East Asia Market Y-o-Y Growth Projections by Cancer Type, 2024 to 2034
Figure 94: East Asia Market Attractiveness Analysis by Cancer Type, 2024 to 2034
Figure 95: East Asia Market Share and BPS Analysis by End User, 2024 & 2034
Figure 96: East Asia Market Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 97: East Asia Market Attractiveness Analysis by End User, 2024 to 2034
Figure 98: South Asia & Pacific Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 99: South Asia & Pacific Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 100: South Asia & Pacific Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 101: South Asia & Pacific Market Incremental $ Opportunity, 2024 to 2034
Figure 102: South Asia & Pacific Market Share Analysis by Country, 2024 & 2034
Figure 103: South Asia & Pacific Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 104: South Asia & Pacific Market Attractiveness Analysis by Country, 2024 to 2034
Figure 105: South Asia & Pacific Market Share and BPS Analysis by Therapy, 2024 & 2034
Figure 106: South Asia & Pacific Market Y-o-Y Growth Projections by Therapy, 2024 to 2034
Figure 107: South Asia & Pacific Market Attractiveness Analysis by Therapy, 2024 to 2034
Figure 108: South Asia & Pacific Market Share and BPS Analysis by Cancer Type, 2024 & 2034
Figure 109: South Asia & Pacific Market Y-o-Y Growth Projections by Cancer Type, 2024 to 2034
Figure 110: South Asia & Pacific Market Attractiveness Analysis by Cancer Type, 2024 to 2034
Figure 111: South Asia & Pacific Market Share and BPS Analysis by End User, 2024 & 2034
Figure 112: South Asia & Pacific Market Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 113: South Asia & Pacific Market Attractiveness Analysis by End User, 2024 to 2034
Figure 114: MEA Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 115: MEA Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 116: MEA Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 117: MEA Market Incremental $ Opportunity, 2024 to 2034
Figure 118: MEA Market Share Analysis by Country, 2024 & 2034
Figure 119: MEA Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 120: MEA Market Attractiveness Analysis by Country, 2024 to 2034
Figure 121: MEA Market Share and BPS Analysis by Therapy, 2024 & 2034
Figure 122: MEA Market Y-o-Y Growth Projections by Therapy, 2024 to 2034
Figure 123: MEA Market Attractiveness Analysis by Therapy, 2024 to 2034
Figure 124: MEA Market Share and BPS Analysis by Cancer Type, 2024 & 2034
Figure 125: MEA Market Y-o-Y Growth Projections by Cancer Type, 2024 to 2034
Figure 126: MEA Market Attractiveness Analysis by Cancer Type, 2024 to 2034
Figure 127: MEA Market Share and BPS Analysis by End User, 2024 & 2034
Figure 128: MEA Market Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 129: MEA Market Attractiveness Analysis by End User, 2024 to 2034
- FAQs -
How big is the cancer immunotherapy market in 2024?
The global cancer immunotherapy market is evaluated at US$ 159.2 billion in 2024.
What is the projected size of the cancer immunotherapy industry by 2034?
The market for cancer immunotherapies is projected to reach US$ 412.8 billion by 2034.
At what rate is the demand for cancer immunotherapies forecasted to rose?
Demand for cancer immunotherapies is foreseen to increase at a CAGR of 10% from 2024 to 2034.
How much is the North American market likely to be valued by 2034?
The North American market is forecasted to reach US$ 100.3 billion by 2034.
How fast is the demand for cancer immunotherapies increasing in Japan?
Cancer immunotherapy demand is calculated to increase at a CAGR of 10.5% in Japan during the next 10 years.
Which type of therapy is widely adopted?
Immune checkpoint inhibitor sales are set to reach US$ 100.7 billion by 2034.
Who are the leading providers of cancer immunotherapies?
Some of the key companies are Pfizer, Inc., Spectrum Pharmaceuticals, Inc., GlaxoSmithKline Plc., Amgen Inc., and Bristol-Myers Squibb Company.
What is the market trend in immunotherapy?
One of the market trends is the development of personalized and combination therapies to offer effective and tailored treatment approaches.
Related Reports
Cancer Immunotherapy Market